<Record>
<Term>Yttrium Y 90 Monoclonal Antibody BrE-3</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Radioimmunoconjugate</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Radiopharmaceutical Compound/Radioimmunoconjugate/Yttrium Y 90 Monoclonal Antibody BrE-3</ClassificationPath>
<BroaderTerm>Radioimmunoconjugate</BroaderTerm>
<BroaderTerm>Radiopharmaceutical Compound</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Yttrium Y 90 Monoclonal Antibody BrE-3</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>MOAB BrE-3, Yttrium Y 90</Synonym>
<Synonym>Yttrium Y 90 Monoclonal Antibody BrE-3</Synonym>
<Description>A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90.  Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation. (NCI04)</Description>
<Source>NCI Thesaurus</Source>
</Record>
